Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 24

Sort by

Sort Order Select

Journal Articles

Efficacy of CAR T-cell therapy is not impaired by previous bispecific antibody treatment in large B-cell lymphoma

Blood (2024) 144 (3): 334–338.

https://doi.org/10.1182/blood.2024024526

Published: 2024

Includes: Supplemental data

Journal Articles

Efficacy of Chimeric Antigen Receptor T-Cell Therapy Is Not Impaired By Previous Bispecific Antibody Treatment in Patients with Large B-Cell Lymphoma

Blood (2023) 142 (Supplement 1): 228.

https://doi.org/10.1182/blood-2023-185035

Published: 2023

Journal Articles

Outcomes of CAR-T Cell Therapy for Large B Cell Lymphoma in Patients of 70 Years and Older: Multicentric Experience on Behalf of Geth-TC/Geltamo

Blood (2023) 142 (Supplement 1): 4883.

https://doi.org/10.1182/blood-2023-185858

Published: 2023

Journal Articles

Varnimcabtagene Autoleucel (ARI-0001) for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) and Richter Transformation (RT)

Blood (2023) 142 (Supplement 1): 3483.

https://doi.org/10.1182/blood-2023-182896

Published: 2023

Journal Articles

Seven-Day Vein-to-Vein Point-of-Care Manufactured CD19 CAR T Cells (GLPG5201) in Relapsed/Refractory CLL/SLL Including Richter's Transformation: Results from the Phase 1 Euplagia-1 Trial

Natalia Tovar, Valentin Ortiz-Maldonado, Nuria Martinez-Cibrian, Sergi Betriu, Daniel Esteban, Ana Triguero, Nadia Verbruggen, Maike Spoon, Marte C. Liefaard, Margot Pont, Anna D.D. van Muyden

Blood (2023) 142 (Supplement 1): 2112.

https://doi.org/10.1182/blood-2023-189321

Published: 2023

Journal Articles

Impact of Salvage and Bridging Therapy in Adult Patients with Refractory B-Cell Acute Lymphoblastic Leukemia (B-ALL) Referred for Anti-CD19 CAR T-Cell Therapy: An Intention to Treat Analysis

Blood (2023) 142 (Supplement 1): 4875.

https://doi.org/10.1182/blood-2023-187226

Published: 2023

Journal Articles

The Post-CAR Prognostic Index (PC-PI): A New Prognostic Score to Predict Overall Survival in Large B-Cell Lymphoma Patients Progressing after Chimeric Antigen Receptor T-Cell Therapy

Blood (2023) 142 (Supplement 1): 227.

https://doi.org/10.1182/blood-2023-184942

Published: 2023

Journal Articles

Female Sex Effect on Anti-CD19 CART Cell Therapy for Relapsed/Refractory B-Cell Lymphoma: A Grupo Español De Trasplante y Terapia Celular (GETH-TC) Study

Blood (2023) 142 (Supplement 1): 6895.

https://doi.org/10.1182/blood-2023-185721

Published: 2023

Journal Articles

Salvage Treatment with Novel Agents Is Preferable to Standard Chemotherapy in Patients with Large B-Cell Lymphoma Progressing after Chimeric Antigen Receptor T-Cell Therapy

Blood (2022) 140 (Supplement 1): 378–380.

https://doi.org/10.1182/blood-2022-169219

Published: 2022

Journal Articles

Impact of Scholar-1 Refractoriness Criteria on the Efficacy of CAR-T Therapy in Aggressive B Cell Lymphoma, Compared with Non-Refractory Patients: A Real World Geltamo/Geth Study

Blood (2022) 140 (Supplement 1): 1849–1851.

https://doi.org/10.1182/blood-2022-166329

Published: 2022

Journal Articles

Easix Application in Adults Undergoing Allogeneic Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide-Based Prophylaxis

Blood (2022) 140 (Supplement 1): 7616–7618.

https://doi.org/10.1182/blood-2022-167051

Published: 2022

Journal Articles

Impact of Ptcy-Based Prophylaxis on Early Infectious Complications in Adults Undergoing Peripheral Blood Allo-HCT

Blood (2022) 140 (Supplement 1): 4730–4732.

https://doi.org/10.1182/blood-2022-170498

Published: 2022

Journal Articles

Role of Allogeneic Hematopoietic Cell Transplant for Relapsed/Refractory Large B-Cell Lymphomas in the CART Era

Blood (2022) 140 (Supplement 1): 665–667.

https://doi.org/10.1182/blood-2022-160000

Published: 2022

Journal Articles

Impressive Reduction of Gvhd Incidence Using Ptcy-TK for Gvhd Prevention in Adults Undergoing 10/10 HLA-Matched Peripheral Blood Allo-HCT

María Queralt Salas, Paola Charry, Nuria Martínez-Cibrian, María Suárez-Lledó, Luis Gerardo Rodríguez-Lobato, Marc Brusosa, María Teresa Solano, Meritxell Nomdedeu, Joan Cid, Miquel Lozano, Jordi Arcarons, Noemí Llobet, Laura Rosinol Dachs, Jordi Esteve, Álvaro Urbano-Ispizua, Enric Carreras, Francesc Fernández-Avilés, Maria Carmen Martinez Munoz, Montserrat Rovira

Blood (2022) 140 (Supplement 1): 4772–4773.

https://doi.org/10.1182/blood-2022-170407

Published: 2022

Journal Articles

Apheresis Products from Patients with Multiple Myeloma Treated with G-CSF Are a Suitable Source of T Cells for the Production of BCMA-Targeting CAR-T Cells

Anthony M Battram, Aina Oliver-Caldés, Miquel Bosch i Crespo, María Suárez-Lledó, Miquel Lozano, Nuria Martínez-Cibrian, Joan Cid, David F. Moreno, Luis Gerardo Rodríguez-Lobato, Alvaro Urbano-Ispizua, Carlos Fernandez de Larrea

Blood (2021) 138 (Supplement 1): 480.

https://doi.org/10.1182/blood-2021-147774

Published: 2021

Journal Articles

Improved GvHD-Free, Relapse-Free Survival (GRFS) with Post-Transplant Cyclophosphamide and Tacrolimus for GvHD Prevention in Older Adults Undergoing Allogeneic Hematopoietic Cell Transplantation

Paola Andrea Charry, Maria Queralt Salas, Alexandra Pedraza, María Suárez-Lledó, Nuria Martínez-Cibrian, Teresa Solano, Ariadna Domenech, Meritxell Nomdedeu, Joan Cid, Miquel Lozano, Laura Rosinol, Francesc Fernández-Avilés, Gonzalo Gutiérrez-García, Enric Carreras, Jordi Esteve, Álvaro Urbano-Ispizua, Montserrat Rovira, Carmen Martínez

Blood (2021) 138 (Supplement 1): 2760.

https://doi.org/10.1182/blood-2021-153366

Published: 2021

Journal Articles

Rreal-World Results from Anti-CD19 CAR-T Cell Therapy for Relapsed or Refractory Diffuse Large B-Cell Lymphoma in Spain and Comparison with Previous Standard of Care: A Geltamo/Geth Study

Blood (2021) 138 (Supplement 1): 3850.

https://doi.org/10.1182/blood-2021-147670

Published: 2021

Journal Articles

Cytopenias in CAR-T Cell Therapy and Use of Transfusion Resources in Adult Patients with Lymphoproliferative Disorders

Lucía Mezquita, Maria Eva Mingot, Patricia Alcalde, Paula Sánchez-Llorca, Javier Camuña-Correa, Juan Luis Reguera, Nuria Martínez-Cibrian, Cristina Blazquez-Goñi, Virginia Escamilla Gomez, Laura Pérez-Ortega, Dolores Serrano, Jose A. Perez-Simon

Blood (2021) 138 (Supplement 1): 3243.

https://doi.org/10.1182/blood-2021-149738

Published: 2021

Journal Articles

Validation of Different Prognostic Scores in Allogeneic Hematopoietic Cell Transplantation in the Post-Transplant Cyclophosphamide Era

Blood (2021) 138 (Supplement 1): 3925.

https://doi.org/10.1182/blood-2021-153069

Published: 2021

Journal Articles

Real-World Evidence of Tisagenlecleucel for the Treatment of Relapsed or Refractory Large B-Cell Lymphoma

Gloria Iacoboni, MD, Josu Iraola-Truchuelo, Nuria Martinez-Cibrian, MD, Rebeca Bailén, MD, Lucia Lopez Corral, PhD MD, Jose M. Sanchez, MD, Manuel Guerreiro, MD, ANA Carolina Carolina CABALLERO González, Alberto Mussetti, MD, Juan-Manuel Sancho, MD PhD, Rafael Hernani, MD, Carlos Solano, MD PhD, Anna Sureda Balari, MD PhD, Javier Briones, MD PhD, Alejandro Martin Garcia-Sancho, MD PhD, Mi Kwon, MD PhD, Juan Luis Reguera, MD PhD, Pere Barba, MD PhD

Blood (2020) 136 (Supplement 1): 19–21.

https://doi.org/10.1182/blood-2020-136201

Published: 2020

NARROW

Efficacy of CAR T-cell therapy is not impaired by previous bispecific antibody treatment in large B-cell lymphoma

Efficacy of Chimeric Antigen Receptor T-Cell Therapy Is Not Impaired By Previous Bispecific Antibody Treatment in Patients with Large B-Cell Lymphoma

Outcomes of CAR-T Cell Therapy for Large B Cell Lymphoma in Patients of 70 Years and Older: Multicentric Experience on Behalf of Geth-TC/Geltamo

Varnimcabtagene Autoleucel (ARI-0001) for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) and Richter Transformation (RT)

Seven-Day Vein-to-Vein Point-of-Care Manufactured CD19 CAR T Cells (GLPG5201) in Relapsed/Refractory CLL/SLL Including Richter's Transformation: Results from the Phase 1 Euplagia-1 Trial

Impact of Salvage and Bridging Therapy in Adult Patients with Refractory B-Cell Acute Lymphoblastic Leukemia (B-ALL) Referred for Anti-CD19 CAR T-Cell Therapy: An Intention to Treat Analysis

The Post-CAR Prognostic Index (PC-PI): A New Prognostic Score to Predict Overall Survival in Large B-Cell Lymphoma Patients Progressing after Chimeric Antigen Receptor T-Cell Therapy

Female Sex Effect on Anti-CD19 CART Cell Therapy for Relapsed/Refractory B-Cell Lymphoma: A Grupo Español De Trasplante y Terapia Celular (GETH-TC) Study

Salvage Treatment with Novel Agents Is Preferable to Standard Chemotherapy in Patients with Large B-Cell Lymphoma Progressing after Chimeric Antigen Receptor T-Cell Therapy

Impact of Scholar-1 Refractoriness Criteria on the Efficacy of CAR-T Therapy in Aggressive B Cell Lymphoma, Compared with Non-Refractory Patients: A Real World Geltamo/Geth Study

Easix Application in Adults Undergoing Allogeneic Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide-Based Prophylaxis

Impact of Ptcy-Based Prophylaxis on Early Infectious Complications in Adults Undergoing Peripheral Blood Allo-HCT

Role of Allogeneic Hematopoietic Cell Transplant for Relapsed/Refractory Large B-Cell Lymphomas in the CART Era

Impressive Reduction of Gvhd Incidence Using Ptcy-TK for Gvhd Prevention in Adults Undergoing 10/10 HLA-Matched Peripheral Blood Allo-HCT

Apheresis Products from Patients with Multiple Myeloma Treated with G-CSF Are a Suitable Source of T Cells for the Production of BCMA-Targeting CAR-T Cells

Improved GvHD-Free, Relapse-Free Survival (GRFS) with Post-Transplant Cyclophosphamide and Tacrolimus for GvHD Prevention in Older Adults Undergoing Allogeneic Hematopoietic Cell Transplantation

Rreal-World Results from Anti-CD19 CAR-T Cell Therapy for Relapsed or Refractory Diffuse Large B-Cell Lymphoma in Spain and Comparison with Previous Standard of Care: A Geltamo/Geth Study

Cytopenias in CAR-T Cell Therapy and Use of Transfusion Resources in Adult Patients with Lymphoproliferative Disorders

Validation of Different Prognostic Scores in Allogeneic Hematopoietic Cell Transplantation in the Post-Transplant Cyclophosphamide Era

Real-World Evidence of Tisagenlecleucel for the Treatment of Relapsed or Refractory Large B-Cell Lymphoma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only